Scarica l'app Stockscreener
4.95
2.56%
-0.13
Dopo l'orario di chiusura:
5.00
0.05
+1.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXST Giù?
Forum
Previsione
Precedente Chiudi:
$5.08
Aprire:
$5.08
Volume 24 ore:
690.16K
Relative Volume:
0.68
Capitalizzazione di mercato:
$204.91M
Reddito:
$134.48M
Utile/perdita netta:
$-38.94M
Rapporto P/E:
-5.1919
EPS:
-0.9534
Flusso di cassa netto:
$-19.34M
1 W Prestazione:
-11.76%
1M Prestazione:
+7.61%
6M Prestazione:
-44.00%
1 anno Prestazione:
-41.49%
Intervallo 1D:
$4.875
$5.11
Intervallo di 1 settimana:
$4.805
$5.90
Portata 52W:
$4.48
$13.22
Rxsight Inc Stock (RXST) Company Profile
Nome
Rxsight Inc
Settore
Industria
Telefono
949-521-7822
Indirizzo
100 COLUMBIA STREET, ALISO VIEJO
Compare RXST vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
4.95 | 204.91M | 134.48M | -38.94M | -19.34M | -0.9534 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Iniziato | William Blair | Mkt Perform |
| 2025-07-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-07-10 | Downgrade | Jefferies | Buy → Hold |
| 2025-07-09 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-07-09 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-07-09 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-04-15 | Iniziato | Piper Sandler | Neutral |
| 2025-04-09 | Downgrade | UBS | Buy → Neutral |
| 2025-04-04 | Downgrade | JP Morgan | Overweight → Underweight |
| 2025-04-03 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-12-20 | Downgrade | Stifel | Buy → Hold |
| 2024-12-11 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | Iniziato | UBS | Buy |
| 2024-10-29 | Iniziato | Jefferies | Buy |
| 2024-08-20 | Reiterato | Needham | Buy |
| 2024-08-06 | Reiterato | Needham | Buy |
| 2024-05-07 | Reiterato | BTIG Research | Buy |
| 2023-12-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-12 | Iniziato | Stifel | Buy |
| 2023-12-04 | Iniziato | Morgan Stanley | Overweight |
| 2023-04-13 | Iniziato | Oppenheimer | Outperform |
| 2022-12-12 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-04-08 | Iniziato | Needham | Buy |
Mostra tutto
Rxsight Inc Borsa (RXST) Ultime notizie
Alcon, RxSight announce collaboration to develop adjustable presbyopia-correcting IOLs - Ophthalmology Times Europe
RxSight Q2 sales sink 20% as Alcon deal bolsters 2026 outlook - MSN
RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook - Yahoo Finance
RxSight (RXST) Faces Investigation Over Board's Fiduciary Duties - GuruFocus
RxSight: After Dropping To The Bottom, It's Time To Pick It Up (NASDAQ:RXST) - Seeking Alpha
Glancy Prongay Wolke & Rotter LLP Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors - The AI Journal
(RXST) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Midday Stock Roundup: Alignment Healthcare Up 7.8% Ahead of Q2 Results - Orange County Business Journal
Alcon collaborates with RxSight to develop adjustable PCIOLs - MSN
Is Alcon (SWX:ALC) Cheap Following Its RxSight Collaboration And Premium P E? - simplywall.st
Is Alcon (SWX:ALC) Undervalued After Its RxSight Collaboration? - Yahoo Finance
Law Offices of Howard G. Smith Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors - FinancialContent
Can Alcon Inc. (ALC) Stock Rebound as New Eye Care Products Approach Regulatory Milestones? - Insider Monkey
RxSight: Alcon Deal Reshapes The Long-Term Growth Story (NASDAQ:RXST) - Seeking Alpha
Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs - InvisionMag.com
Price to book forward of RxSight, Inc. – NASDAQ:RXST - TradingView
RxSight, Inc. Reports Preliminary Financial Results for the Second Quarter of 2026 - VisionMonday.com
Price to sales forward of RxSight, Inc. – NASDAQ:RXST - TradingView
Alcon and RxSight partner to to develop light-adjustable PCIOLs - Eyes On Eyecare
ALC News & Events - Intellectia AI
Enterprise value to EBIT forward of RxSight, Inc. – NASDAQ:RXST - TradingView
RxSight (RXST) Adjusts FY26 Revenue Forecast Amid Collaboration Insights - GuruFocus
The Law Offices of Frank R. Cruz Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors - Business Wire
RXST Maintained by B of A Securities -- Price Target Lowered to $6.50 - GuruFocus
BofA cuts RxSight stock price target on weak Q2 sales, guidance - Investing.com Nigeria
BofA cuts RxSight stock price target on weak Q2 sales, guidance By Investing.com - Investing.com South Africa
RxSight Announces Preliminary Q2 Results - Orange County Business Journal
RxSight Inc. (RXST) PT Lowered to $6.50 at BofA Securities - StreetInsider
RxSight, Inc. Provides Preliminary Revenue Guidance for the Second Quarter Ended June 30, 2026 - marketscreener.com
RxSight stock tumbles on reduced 2026 sales guidance By Investing.com - Investing.com South Africa
Alcon, RxSight Begin Co-Developing Presbyopia-Correcting IOLs - Medical Product Outsourcing
Stifel reiterates Hold on RxSight stock, $8 target on Alcon deal By Investing.com - Investing.com South Africa
Stifel reiterates Hold on RxSight stock, $8 target on Alcon deal - Investing.com
Rxsight Q2 Revenue USD 27 Million Vs. IBES Es - Moomoo
Alcon spends up to $200m to co-develop customisable cataract lenses with RxSight - Yahoo Finance
RxSight reports preliminary Q2 revenue, revises 2026 guidance - MSN
RxSight (RXST) Reiterated at Hold by Stifel as ALC Collaboration Announced - StreetInsider
Rivian Automotive, Penguin Solutions And 3 Stocks To Watch Heading Into Tuesday - Benzinga
RXST: 2026 revenue guidance lowered, gross margin raised, and next-gen lens pipeline advances - TradingView
Alcon, RxSight Partner to Develop Adjustable Presbyopia-Correcting IOLs - VisionMonday.com
RxSight raises FY26 sales guidance to $140M-$160M - scanx.trade
Alcon, RxSight partner on adjustable lens technology - Investing.com UK
Alcon, RxSight partner on adjustable lens technology By Investing.com - Investing.com South Africa
Alcon (ALC) Partners with RxSight for Innovative Lens Developmen - GuruFocus
RxSight reports Q2 revenue of $32-34M, cuts 2026 sales outlook - Investing.com
ALCON AGRXSIGHT TO RECEIVE $60 MLN UPFRONT PAYMENT UNDER AGREEMENT - Moomoo
RxSight says Q2 results hit by more widespread competitive trialing - TradingView
RxSight cuts 2026 sales outlook, citing competitive headwinds - StreetInsider
RxSight (NASDAQ: RXST) cuts 2026 sales outlook but lifts margin view - Stock Titan
Rxsight, Inc. Updates Revenue Guidance for the Full Year 2026 - marketscreener.com
Join Class Action to Recover Losses From RxSight, Inc. (RXST)Contact Levi & Korsinsky Before September 22, 2025 - The National Law Review
Rxsight Inc Azioni (RXST) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.36%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):